Vigil ST - Gradalis
Alternative Names: Vigil-STLatest Information Update: 28 Jul 2023
At a glance
- Originator Gradalis; Mary Crowley Cancer Research Center
- Developer Gradalis
- Class Cancer vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Intradermal)
- 22 Jul 2021 Phase I development is ongoing in USA (Gradalis pipeline July 2021)